Alexander N Shoushtari
Overview
Explore the profile of Alexander N Shoushtari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
9134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shoushtari A, Powell D
Transplant Cell Ther
. 2025 Mar;
31(3S):S581-S590.
PMID: 40089327
Lifileucel, the first solid tumor adoptive tumor infiltrating lymphocyte (TIL) therapy product to receive regulatory approval in advanced melanoma, represents a critical achievement in the pursuit of improving outcomes using...
2.
Avutu V, Algazaq J, Seier K, Desir-Camille R, Qin L, Babatunde O, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39993596
Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are...
3.
Aprati T, Day C, Lee D, Pan A, Jee J, Tarantino G, et al.
bioRxiv
. 2025 Feb;
PMID: 39975034
Metastasis drives mortality and morbidity in cancer. While some patients develop broad metastatic disease across multiple organs, others exhibit organ-specific spread. To identify mechanisms underlying metastatic organotropism, we analyzed clinico-genomic...
4.
Lochrin S, Kalvin H, Smithy J, Chen M, Momtaz P, Shoushtari A, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39883427
No abstract available.
5.
Gormally M, Chen M, Noronha A, Panageas K, Reynolds M, Kohlasch K, et al.
JAMA Oncol
. 2024 Nov;
11(1):74-76.
PMID: 39602136
No abstract available.
6.
Kudelka M, Richards A, Friedlander P, Wolchok J, Moy A, Shoushtari A
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39551602
Melanoma arising in association with a blue nevus (BN) is rare but has molecular similarities to uveal melanoma (UM), including GNAQ/11 mutations. Tebentafusp was recently approved for UM based on...
7.
Haghani L, Zhan C, Yarmohammadi H, Ziv E, Sotirchos V, Sarkar D, et al.
Immunotherapy
. 2024 Sep;
16(14-15):955-962.
PMID: 39225651
To investigate how the sequence of checkpoint immunotherapy (CPI) and transarterial embolization (TAE) affects overall survival (OS) of patients with metastatic melanoma. This retrospective cohort study included 65 patients with...
8.
Barker C, DAngelo S, Wasilewski G, Steckler A, Lian M, Zhang Z, et al.
Radiother Oncol
. 2024 Aug;
200:110478.
PMID: 39159678
Background: Cutaneous metastases (CMs) are a manifestation of advanced cancer and can be treated with oncolytic immunotherapy. Laboratory studies suggest radiotherapy (RT) may facilitate response to immunotherapy. We hypothesized that...
9.
Lochrin S, Buonocore D, Young R, Kaley T, Postow M, Wolchok J, et al.
Pigment Cell Melanoma Res
. 2024 Jul;
37(6):801-807.
PMID: 38960393
Leptomeningeal disease (LMD) is a devastating complication of melanoma with a dismal prognosis. We present the case of a young man with stage IV BRAF V600E mutant melanoma with lung,...
10.
Lochrin S, Cugliari M, Yeh R, Shoushtari A
Melanoma Res
. 2024 Jul;
34(5):450-456.
PMID: 38953532
Mucosal melanoma is a rare melanoma subtype, accounting for about 1% of all diagnosed melanomas. It is characterized by an aggressive phenotype with a poor prognosis and a low response...